Skeletal muscle abnormalities in heart failure

International Heart Journal

Volumn 56, Issue 5, 2015, Pages 475-484

  Kinugawa, Shintaro ^a   Takada, Shingo ^a   Matsushima, Shouji ^a   Okita, Koichi ^b   Tsutsui, Hiroyuki ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HOKUSHO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

AGED; ANGIOCARDIOGRAPHY; ARTERY DIAMETER; CATHETER SHEATH; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ECHOGRAPHY; ENDOTHELIAL DYSFUNCTION; FEMALE; GLOMERULUS FILTRATION RATE; HEART CATHETERIZATION; HUMAN; HYPEREMIA; MALE; PERIPHERAL ARTERIAL TONOMETRY; PRIORITY JOURNAL; RADIAL ARTERY; REACTIVE HYPEREMIA PERIPHERAL ARTERIAL TONOMETRY; REVIEW; DAILY LIFE ACTIVITY; ENERGY METABOLISM; EXERCISE TOLERANCE; HEART FAILURE; METABOLISM; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROGNOSIS; PSYCHOLOGY; QUALITY OF LIFE; SKELETAL MUSCLE;

ACTIVITIES OF DAILY LIVING; ENERGY METABOLISM; EXERCISE TOLERANCE; HEART FAILURE; HUMANS; MUSCLE, SKELETAL; OXIDATIVE STRESS; PROGNOSIS; QUALITY OF LIFE;

EID: 84942887670     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.15-108     Document Type: Review

References (134)

1. Scott W, Stevens J, Binder-Macleod SA. Human skeletal muscle fiber type classifications. Phys Ther 2001; 81: 1810-6. (Review) 2. Sen CK. Oxidants and antioxidants in exercise. J Appl Physiol (1985) 1995; 79: 675-86. (Review)
2. Rasmussen UF, Rasmussen HN, Krustrup P, Quistorff B, Saltin B, Bangsbo J. Aerobic metabolism of human quadriceps muscle: in vivo data parallel measurements on isolated mitochondria. Am J Physiol Endocrinol Metab 2001; 280: E301-7.
3. Okita K, Nishijima H, Yonezawa K, et al. Skeletal muscle metabolism in maximal bicycle and treadmill exercise distinguished by using in vivo metabolic freeze method and phosphorus-31 magnetic resonance spectroscopy in normal men. Am J Cardiol 1998; 81: 106-9.
4. Okita K, Yonezawa K, Nishijima H, et al. Skeletal muscle metabolism limits exercise capacity in patients with chronic heart failure. Circulation 1998; 98: 1886-91.
5. Koopman R, van Loon LJ. Aging, exercise, and muscle protein metabolism. J Appl Physiol (1985) 2009; 106: 2040-8. (Review)
6. Myers J, Prakash M, Froelicher V, Do D, Partington S, Atwood JE. Exercise capacity and mortality among men referred for exercise testing. N Engl J Med 2002; 346: 793-801.
7. Wei M, Gibbons LW, Kampert JB, Nichaman MZ, Blair SN. Low cardiorespiratory fitness and physical inactivity as predictors of mortality in men with type 2 diabetes. Ann Intern Med 2000; 132: 605-11.
8. Mancini DM, Eisen H, Kussmaul W, Mull R, Edmunds LH Jr, Wilson JR. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 1991; 83: 778-86.
9. Heitmann BL, Frederiksen P. Thigh circumference and risk of heart disease and premature death: prospective cohort study. BMJ 2009; 339: b3292.
10. Newman AB, Kupelian V, Visser M, et al. Strength, but not muscle mass, is associated with mortality in the health, aging and body composition study cohort. J Gerontol A Biol Sci Med Sci 2006; 61: 72-7.
11. Hulsmann M, Quittan M, Berger R, et al. Muscle strength as a predictor of long-term survival in severe congestive heart failure. Eur J Heart Fail 2004; 6: 101-7.
12. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010; 39: 412-23.
13. Muscaritoli M, Anker SD, Argilés J, et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) “cachexia-anorexia in chronic wasting diseases” and “nutrition in geriatrics”. Clin Nutr 2010; 29: 154-9.
14. Cawthon PM, Marshall LM, Michael Y, et al. Frailty in older men: prevalence, progression, and relationship with mortality. J Am Geriatr Soc 2007; 55: 1216-23.
15. Egan B, Zierath JR. Exercise metabolism and the molecular regulation of skeletal muscle adaptation. Cell Metab 2013; 17: 162-84. (Review)
16. Tadaishi M, Miura S, Kai Y, Kano Y, Oishi Y, Ezaki O. Skeletal muscle-specific expression of PGC-1alpha-b, an exercise-responsive isoform, increases exercise capacity and peak oxygen uptake. PLoS One 2011; 6: e28290.
17. Kang D, Kim SH, Hamasaki N. Mitochondrial transcription factor A (TFAM): roles in maintenance of mtDNA and cellular functions. Mitochondrion 2007; 7: 39-44. (Review)
18. Ngo HB, Kaiser JT, Chan DC. The mitochondrial transcription and packaging factor Tfam imposes a U-turn on mitochondrial DNA. Nat Struct Mol Biol 2011; 18: 1290-6.
19. Calvo JA, Daniels TG, Wang X, et al. Muscle-specific expression of PPARgamma coactivator-1alpha improves exercise performance and increases peak oxygen uptake. J Appl Physiol (1985) 2008; 104: 1304-12.
20. Lin J, Wu H, Tarr PT, et al. Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature 2002; 418: 797-801.
21. Wende AR, Schaeffer PJ, Parker GJ, et al. A role for the transcriptional coactivator PGC-1alpha in muscle refueling. J Biol Chem 2007; 282: 36642-51.
22. Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 2005; 1: 15-25. (Review)
23. Gibala MJ, McGee SL, Garnham AP, Howlett KF, Snow RJ, Hargreaves M. Brief intense interval exercise activates AMPK and p38 MAPK signaling and increases the expression of PGC-1alpha in human skeletal muscle. J Appl Physiol (1985) 2009; 106: 929-34.
24. Lee HY, Choi CS, Birkenfeld AL, et al. Targeted expression of catalase to mitochondria prevents age-associated reductions in mitochondrial function and insulin resistance. Cell Metab 2010; 12: 668-74.
25. Narkar VA, Downes M, Yu RT, et al. AMPK and PPARdelta agonists are exercise mimetics. Cell 2008; 134: 405-15.
26. Jager S, Handschin C, St-Pierre J and Spiegelman BM. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc Natl Acad Sci U S A 2007; 104: 12017-22.
27. Lantier L, Fentz J, Mounier R, et al. AMPK controls exercise endurance, mitochondrial oxidative capacity, and skeletal muscle integrity. FASEB J 2014; 28: 3211-24.
28. Price NL, Gomes AP, Ling AJ, et al. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab 2012; 15: 675-90.
29. Schwer B, Verdin E. Conserved metabolic regulatory functions of sirtuins. Cell Metab 2008; 7: 104-12. (Review)
30. Cantó C, Jiang LQ, Deshmukh AS, et al. Interdependence of AMPK and SIRT1 for metabolic adaptation to fasting and exercise in skeletal muscle. Cell Metab 2010; 11: 213-9.
31. Hirschey MD, Shimazu T, Jing E, et al. SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome. Mol Cell 2011; 44: 177-90.
32. Schwer B, North BJ, Frye RA, Ott M, Verdin E. The human silent information regulator (Sir)2 homologue hSIRT3 is a mitochondrial nicotinamide adenine dinucleotide-dependent deacetylase. J Cell Biol 2002; 158: 647-57.
33. Agarwal B, Baur JA. Resveratrol and life extension. Ann N Y Acad Sci 2011; 1215: 138-43. (Review)
34. Palacios OM, Carmona JJ, Michan S, et al. Diet and exercise signals regulate SIRT3 and activate AMPK and PGC-1alpha in skeletal muscle. Aging 2009; 1: 771-83.
35. Dolinsky VW, Jones KE, Sidhu RS, et al. Improvements in skeletal muscle strength and cardiac function induced by resveratrol during exercise training contribute to enhanced exercise performance in rats. J Physiol 2012; 590: 2783-99.
36. Hart N, Sarga L, Csende Z, et al. Resveratrol enhances exercise training responses in rats selectively bred for high running performance. Food Chem Toxicol 2013; 61: 53-9.
37. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 2005; 434: 113-8.
38. Philp A, Chen A, Lan D, et al. Sirtuin 1 (SIRT1) deacetylase activity is not required for mitochondrial biogenesis or peroxisome proliferator-activated receptor-gamma coactivator-1alpha (PGC- 1alpha) deacetylation following endurance exercise. J Biol Chem 2011; 286: 30561-70.
39. Iwabu M, Yamauchi T, Okada-Iwabu M, et al. Adiponectin and AdipoR1 regulate PGC-1alpha and mitochondria by Ca(2+) and AMPK/SIRT1. Nature 2010; 464: 1313-9.
40. Lee-Young RS, Ayala JE, Hunley CF, et al. Endothelial nitric oxide synthase is central to skeletal muscle metabolic regulation and enzymatic signaling during exercise in vivo. Am J Physiol Regul Integr Comp Physiol 2010; 298: R1399-408.
41. Nisoli E, Clementi E, Paolucci C, et al. Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide. Science 2003; 299: 896-9.
42. Nisoli E, Tonello C, Cardile A, et al. Calorie restriction promotes mitochondrial biogenesis by inducing the expression of eNOS. Science 2005; 310: 314-7.
43. Egan B, Carson BP, Garcia-Roves PM, et al. Exercise intensitydependent regulation of peroxisome proliferator-activated receptor coactivator-1 mRNA abundance is associated with differential activation of upstream signalling kinases in human skeletal muscle. J Physiol 2010; 588: 1779-90.
44. Wu H, Kanatous SB, Thurmond FA, et al. Regulation of mitochondrial biogenesis in skeletal muscle by CaMK. Science 2002; 296: 349-52.
45. Akimoto T, Okuhira K, Aizawa K, et al. Skeletal muscle adaptation in response to mechanical stress in p130cas-/- mice. Am J Physiol Cell Physiol 2013; 304: C541-7.
46. Akimoto T, Pohnert SC, Li P, et al. Exercise stimulates Pgc-1alpha transcription in skeletal muscle through activation of the p38 MAPK pathway. J Biol Chem 2005; 280: 19587-93.
47. Pogozelski AR, Geng T, Li P, et al. p38gamma mitogen-activated protein kinase is a key regulator in skeletal muscle metabolic adaptation in mice. PLoS One 2009; 4: e7934.
48. Goldspink DF, Garlick PJ, McNurlan MA. Protein turnover measured in vivo and in vitro in muscles undergoing compensatory growth and subsequent denervation atrophy. Biochem J 1983; 210: 89-98.
49. DeVol DL, Rotwein P, Sadow JL, Novakofski J, Bechtel PJ. Activation of insulin-like growth factor gene expression during workinduced skeletal muscle growth. Am J Physiol 1990; 259: E89-95.
50. Coleman ME, DeMayo F, Yin KC, et al. Myogenic vector expression of insulin-like growth factor I stimulates muscle cell differentiation and myofiber hypertrophy in transgenic mice. J Biol Chem 1995; 270: 12109-16.
51. Musarò A, McCullagh K, Paul A, et al. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet 2001; 27: 195-200.
52. Lai KM, Gonzalez M, Poueymirou WT, et al. Conditional activation of akt in adult skeletal muscle induces rapid hypertrophy. Mol Cell Biol 2004; 24: 9295-304.
53. Peng XD, Xu PZ, Chen ML, et al. Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes Dev 2003; 17: 1352-65.
54. Egerman MA, Glass DJ. Signaling pathways controlling skeletal muscle mass. Crit Rev Biochem Mol Biol 2014; 49: 59-68.
55. Kim DH, Sarbassov DD, Ali SM, et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002; 110: 163-75.
56. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307: 1098-101.
57. Sarbassov DD, Sabatini DM. Redox regulation of the nutrientsensitive raptor-mTOR pathway and complex. J Biol Chem 2005; 280: 39505-9.
58. Baar K, Esser K. Phosphorylation of p70(S6k) correlates with increased skeletal muscle mass following resistance exercise. Am J Physiol 1999; 276: C120-7.
59. Guertin DA, Stevens DM, Thoreen CC, et al. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell 2006; 11: 859-71.
60. Lamming DW, Ye L, Katajisto P, et al. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 2012; 335: 1638-43.
61. Alessi DR, Caudwell FB, Andjelkovic M, Hemmings BA, Cohen P Molecular basis for the substrate specificity of protein kinase B; comparison with MAPKAP kinase-1 and p70 S6 kinase. FEBS Lett 1996; 399: 333-8.
62. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995; 378: 785-9.
63. Hardt SE, Tomita H, Katus HA, Sadoshima J. Phosphorylation of eukaryotic translation initiation factor 2Bepsilon by glycogen synthase kinase-3beta regulates beta-adrenergic cardiac myocyte hypertrophy. Circ Res 2004; 94: 926-35.
64. Morisco C, Zebrowski D, Condorelli G, Tsichlis P, Vatner SF, Sadoshima J. The Akt-glycogen synthase kinase 3beta pathway regulates transcription of atrial natriuretic factor induced by betaadrenergic receptor stimulation in cardiac myocytes. J Biol Chem 2000; 275: 14466-75.
65. Rommel C, Bodine SC, Clarke BA, et al. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat Cell Biol 2001; 3: 1009-13.
66. McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 1997; 387: 83-90.
67. Trendelenburg AU, Meyer A, Rohner D, Boyle J, Hatakeyama S, Glass DJ. Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size. Am J Physiol Cell Physiol 2009; 296: C1258-70.
68. Sartori R, Milan G, Patron M, et al. Smad2 and 3 transcription factors control muscle mass in adulthood. Am J Physiol Cell Physiol 2009; 296: C1248-57.
69. Zhao B, Wall RJ, Yang J. Transgenic expression of myostatin propeptide prevents diet-induced obesity and insulin resistance. Biochem Biophys Res Commun 2005; 337: 248-55.
70. Morissette MR, Cook SA, Buranasombati C, Rosenberg MA, Rosenzweig A. Myostatin inhibits IGF-I-induced myotube hypertrophy through Akt. Am J Physiol Cell Physiol 2009; 297: C1124-32.
71. Awede BL, Thissen JP, Lebacq J. Role of IGF-I and IGFBPs in the changes of mass and phenotype induced in rat soleus muscle by clenbuterol. Am J Physiol Endocrinol Metab 2002; 282: E31-7.
72. Kline WO, Panaro FJ, Yang H, Bodine SC. Rapamycin inhibits the growth and muscle-sparing effects of clenbuterol. J Appl Physiol (1985) 2007; 102: 740-7.
73. Sneddon AA, Delday MI, Steven J, Maltin CA. Elevated IGF-II mRNA and phosphorylation of 4E-BP1 and p70(S6k) in muscle showing clenbuterol-induced anabolism. Am J Physiol Endocrinol Metab 2001; 281: E676-82.
74. von Maltzahn J, Bentzinger CF, Rudnicki MA. Wnt7a-Fzd7 signalling directly activates the Akt/mTOR anabolic growth pathway in skeletal muscle. Nat Cell Biol 2012; 14: 186-91.
75. Minetti GC, Feige JN, Bombard F, et al. Galphai2 signaling is required for skeletal muscle growth, regeneration, and satellite cell proliferation and differentiation. Mol Cell Biol 2014; 34: 619-30.
76. Bodine SC, Latres E, Baumhueter S, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001; 294: 1704-8.
77. Urso ML, Chen YW, Scrimgeour AG, Lee PC, Lee KF, Clarkson PM. Alterations in mRNA expression and protein products following spinal cord injury in humans. J Physiol 2007; 579: 877-92.
78. Minetti GC, Feige JN, Rosenstiel A, et al. Galphai2 signaling promotes skeletal muscle hypertrophy, myoblast differentiation, and muscle regeneration. Sci Signal 2011; 4: ra80.
79. Sishi BJ, Engelbrecht AM. Tumor necrosis factor alpha (TNF-α) inactivates the PI3-kinase/PKB pathway and induces atrophy and apoptosis in L6 myotubes. Cytokine 2011; 54: 173-84.
80. Wang DT, Yin Y, Yang YJ, et al. Resveratrol prevents TNF-α- induced muscle atrophy via regulation of Akt/mTOR/FoxO1 signaling in C2C12 myotubes. Int Immunopharmacol 2014; 19: 206-13.
81. Mittal A, Bhatnagar S, Kumar A, et al. The TWEAK-Fn14 system is a critical regulator of denervation-induced skeletal muscle atrophy in mice. J Cell Biol 2010; 188: 833-49.
82. Cai D, Frantz JD, Tawa NE Jr, et al. IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell 2004; 119: 285-98.
83. Kubica N, Bolster DR, Farrell PA, Kimball SR, Jefferson LS. Resistance exercise increases muscle protein synthesis and translation of eukaryotic initiation factor 2Bepsilon mRNA in a mammalian target of rapamycin-dependent manner. J Biol Chem 2005; 280: 7570-80.
84. Moore-Carrasco R, Busquets S, Almendro V, Palanki M, López- Soriano FJ, Argilés JM. The AP-1/NF-kappaB double inhibitor SP100030 can revert muscle wasting during experimental cancer cachexia. Int J Oncol 2007; 30: 1239-45.
85. Li YP, Chen Y, John J, et al. TNF-alpha acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle. FASEB J 2005; 19: 362-70.
86. Schakman O, Kalista S, Barbé C, Loumaye A, Thissen JP. Glucocorticoid- induced skeletal muscle atrophy. Int J Biochem Cell Biol 2013; 45: 2163-72. (Review)
87. Castillero E, Alamdari N, Lecker SH, Hasselgren PO. Suppression of atrogin-1 and MuRF1 prevents dexamethasone-induced atrophy of cultured myotubes. Metabolism 2013; 62: 1495-502.
88. Stitt TN, Drujan D, Clarke BA, et al. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 2004; 14: 395-403.
89. Okita K, Kinugawa S, Tsutsui H. Exercise intolerance in chronic heart failure--skeletal muscle dysfunction and potential therapies. Circ J 2013; 77: 293-300. (Review)
90. Hirabayashi K, Kinugawa S, Yokota T, et al. Intramyocellular lipid is increased in the skeletal muscle of patients with dilated cardiomyopathy with lowered exercise capacity. Int J Cardiol 2014; 176: 1110-2.
91. Clark AL, Poole-Wilson PA, Coats AJ. Exercise limitation in chronic heart failure: central role of the periphery. J Am Coll Cardiol 1996; 28: 1092-102. (Review)
92. Middlekauff HR. Making the case for skeletal myopathy as the major limitation of exercise capacity in heart failure. Circ Heart Fail 2010; 3: 537-46. (Review)
93. Vescovo G, Serafini F, Facchin L, et al. Specific changes in skeletal muscle myosin heavy chain composition in cardiac failure: differences compared with disuse atrophy as assessed on microbiopsies by high resolution electrophoresis. Heart 1996; 76: 337-43.
94. Franssen FM, Wouters EF, Schols AM. The contribution of starvation, deconditioning and ageing to the observed alterations in peripheral skeletal muscle in chronic organ diseases. Clin Nutr 2002; 21: 1-14. (Review)
95. Duscha BD, Schulze PC, Robbins JL, Forman DE. Implications of chronic heart failure on peripheral vasculature and skeletal muscle before and after exercise training. Heart Fail Rev 2008; 13: 21-37. (Review)
96. Sullivan MJ, Green HJ, Cobb FR. Skeletal muscle biochemistry and histology in ambulatory patients with long-term heart failure. Circulation 1990; 81: 518-27.
97. Dalla Libera L, Vescovo G, Volterrani M. Physiological basis for contractile dysfunction in heart failure. Curr Pharm Des 2008; 14: 2572-81. (Review)
98. Bechara LR, Moreira JB, Jannig PR, et al. NADPH oxidase hyperactivity induces plantaris atrophy in heart failure rats. Int J Cardiol 2014; 175: 499-507.
99. Schulze PC, Fang J, Kassik KA, et al. Transgenic overexpression of locally acting insulin-like growth factor-1 inhibits ubiquitinmediated muscle atrophy in chronic left-ventricular dysfunction. Circ Res 2005; 97: 418-26.
100. Voltarelli VA, Bechara LR, Bacurau AV, et al. Lack of β2 -adrenoceptors aggravates heart failure-induced skeletal muscle myopathy in mice. J Cell Mol Med 2014; 18: 1087-97.
101. Fukushima A, Kinugawa S, Takada S, et al. (Pro)renin receptor in skeletal muscle is involved in the development of insulin resistance associated with postinfarct heart failure in mice. Am J Physiol Endocrinol Metab 2014; 307: E503-14.
102. Ohta Y, Kinugawa S, Matsushima S, et al. Oxidative stress impairs insulin signal in skeletal muscle and causes insulin resistance in postinfarct heart failure. Am J Physiol Heart Circ Physiol 2011; 300: H1637-44.
103. Song YH, Li Y, Du J, Mitch WE, Rosenthal N, Delafontaine P. Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting. J Clin Invest 2005; 115: 451-8.
104. Heineke J, Auger-Messier M, Xu J, et al. Genetic deletion of myostatin from the heart prevents skeletal muscle atrophy in heart failure. Circulation 2010; 121: 419-25.
105. De Sousa E, Lechêne P, Fortin D, et al. Cardiac and skeletal muscle energy metabolism in heart failure: beneficial effects of voluntary activity. Cardiovasc Res 2002; 56: 260-8.
106. De Sousa E, Veksler V, Bigard X, Mateo P, Ventura-Clapier R. Heart failure affects mitochondrial but not myofibrillar intrinsic properties of skeletal muscle. Circulation 2000; 102: 1847-53.
107. Delp MD, Duan C, Mattson JP, Musch TI. Changes in skeletal muscle biochemistry and histology relative to fiber type in rats with heart failure. J Appl Physiol (1985) 1997; 83: 1291-9.
108. Enache I, Charles AL, Bouitbir J, et al. Skeletal muscle mitochondrial dysfunction precedes right ventricular impairment in experimental pulmonary hypertension. Mol Cell Biochem 2013; 373: 161-70.
109. Rimbaud S, Ruiz M, Piquereau J, et al. Resveratrol improves survival, hemodynamics and energetics in a rat model of hypertension leading to heart failure. PLoS One 2011; 6: e26391.
110. Rosca MG, Okere IA, Sharma N, Stanley WC, Recchia FA, Hoppel CL. Altered expression of the adenine nucleotide translocase isoforms and decreased ATP synthase activity in skeletal muscle mitochondria in heart failure. J Mol Cell Cardiol 2009; 46: 927-35.
111. Sabbah HN, Hansen-Smith F, Sharov VG, et al. Decreased proportion of type I myofibers in skeletal muscle of dogs with chronic heart failure. Circulation 1993; 87: 1729-37.
112. Schrepper A, Schwarzer M, Schöpe M, Amorim PA, Doenst T. Biphasic response of skeletal muscle mitochondria to chronic cardiac pressure overload - role of respiratory chain complex activity. J Mol Cell Cardiol 2012; 52: 125-35.
113. Wüst RC, Myers DS, Stones R, et al. Regional skeletal muscle remodeling and mitochondrial dysfunction in right ventricular heart failure. Am J Physiol Heart Circ Physiol 2012; 302: H402-11.
114. Zoll J, Monassier L, Garnier A, et al. ACE inhibition prevents myocardial infarction-induced skeletal muscle mitochondrial dysfunction. J Appl Physiol (1985) 2006; 101: 385-91.
115. Inoue N, Kinugawa S, Suga T, et al. Angiotensin II-induced reduction in exercise capacity is associated with increased oxidative stress in skeletal muscle. Am J Physiol Heart Circ Physiol 2012; 302: H1202-10.
116. Kadoguchi T, Kinugawa S, Takada S, et al. Angiotensin II can directly induce mitochondrial dysfunction, decrease oxidative fibre number and induce atrophy in mouse hindlimb skeletal muscle. Exp Physiol 2015; 100: 312-22.
117. Granger CB, Califf RM, Young S, et al. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. J Am Coll Cardiol 1993; 21: 920-5.
118. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34.
119. Matsushima S, Kinugawa S, Yokota T, et al. Increased myocardial NAD(P)H oxidase-derived superoxide causes the exacerbation of postinfarct heart failure in type 2 diabetes. Am J Physiol Heart Circ Physiol 2009; 297: H409-16.
120. Kemppainen J, Tsuchida H, Stolen K, et al. Insulin signalling and resistance in patients with chronic heart failure. J Physiol 2003; 550: 305-15.
121. Paolisso G, Tagliamonte MR, Rizzo MR, et al. Prognostic importance of insulin-mediated glucose uptake in aged patients with congestive heart failure secondary to mitral and/or aortic valve disease. Am J Cardiol 1999; 83: 1338-44.
122. Witteles RM, Tang WH, Jamali AH, Chu JW, Reaven GM, Fowler MB. Insulin resistance in idiopathic dilated cardiomyopathy: a possible etiologic link. J Am Coll Cardiol 2004; 44: 78-81.
123. Yokota T, Kinugawa S, Okita K, et al. Lower aerobic capacity was associated with abnormal intramuscular energetics in patients with metabolic syndrome. Hypertens Res 2011; 34: 1029-34.
124. Yokota T, Kinugawa S, Yamato M, et al. Systemic oxidative stress is associated with lower aerobic capacity and impaired skeletal muscle energy metabolism in patients with metabolic syndrome. Diabetes Care 2013; 36: 1341-6.
125. Suga T, Kinugawa S, Takada S, et al. Combination of exercise training and diet restriction normalizes limited exercise capacity and impaired skeletal muscle function in diet-induced diabetic mice. Endocrinology 2014; 155: 68-80.
126. Takada S, Hirabayashi K, Kinugawa S, et al. Pioglitazone ameliorates the lowered exercise capacity and impaired mitochondrial function of the skeletal muscle in type 2 diabetic mice. Eur J Pharmacol 2014; 740: 690-6.
127. Takada S, Kinugawa S, Hirabayashi K, et al. Angiotensin II receptor blocker improves the lowered exercise capacity and impaired mitochondrial function of the skeletal muscle in type 2 diabetic mice. J Appl Physiol (1985) 2013; 114: 844-57.
128. Yokota T, Kinugawa S, Hirabayashi K, et al. Oxidative stress in skeletal muscle impairs mitochondrial respiration and limits exercise capacity in type 2 diabetic mice. Am J Physiol Heart Circ Physiol 2009; 297: H1069-77.
129. de Las Heras N, Valero- Muñoz M, Ballesteros S, et al. Factors involved in rosuvastatin induction of insulin sensitization in rats fed a high fat diet. Nutr Metab Cardiovasc Dis 2013; 23: 1107-14.
130. Escande C, Chini CC, Nin V, et al. Deleted in breast cancer-1 regulates SIRT1 activity and contributes to high-fat diet-induced liver steatosis in mice. J Clin Invest 2010; 120: 545-58.
131. Kumagai H, Kubota N, Kubota T, et al. Combined treatment with low-dose pioglitazone and beraprost sodium improves glucose intolerance without causing body weight gain. Diabetol Int 2013; 4: 226-32.
132. Lee S, Zhang H, Chen J, Dellsperger KC, Hill MA, Zhang C. Adiponectin abates diabetes-induced endothelial dysfunction by suppressing oxidative stress, adhesion molecules, and inflammation in type 2 diabetic mice. Am J Physiol Heart Circ Physiol 2012; 303: H106-15.
133. Lin Z, Tian H, Lam KS, et al. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab 2013; 17: 779-89.
134. Safwat Y, Yassin N, Gamal El Din M, Kassem L. Modulation of skeletal muscle performance and SERCA by exercise and adiponectin gene therapy in insulin-resistant rat. DNA Cell Biol 2013; 32: 378-85.